

REMARKS / ARGUMENTS


In response to the restriction requirement under 35 USC 121 and 372, Applicants elect the claims of Group II, with traverse.

Claim 1 specifies that (a) is a vasculostatic compound of unspecified structure. Applicants further direct the Examiner's attention to U.S. Patent No. 6,710,047. In view of the '047 patent, Applicant asserts that the Examiner has not established that it would be an undue burden to search the full scope of formula I.

Entry of this paper is requested and an action on the merits is awaited.

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824

Respectfully submitted,

A handwritten signature in black ink, appearing to read "George R. Dohmann", written over a horizontal line.

George R. Dohmann  
Attorney for Applicant  
Reg. No. 33,593

Date: **May 13, 2008**